Circulatory Shock & Vasoactive Pharmacology
Core concept: Shock pharmacotherapy restores oxygen delivery by correcting the underlying hemodynamic failure – inadequate preload, contractility, vascular tone, or mechanical obstruction – rather than treating a blood-pressure number in isolation.
Key clinical distinction: Fluids, blood products, vasopressors, and inotropes can improve the same MAP through very different mechanisms. The correct therapy depends on shock phenotype and whether the patient needs more preload, more vascular tone, more cardiac output, or definitive relief of obstruction.
Prescribing priority: Classify the shock state, correct the cause, titrate resuscitation to perfusion endpoints, and minimize the harms of excess fluid, excessive vasoconstriction, and unnecessary catecholamine exposure.
Classify the Hemodynamic Problem
Shock phenotype | Primary hemodynamic problem | Pharmacotherapy implication |
|---|---|---|
Hypovolemic | Low preload → low stroke volume / cardiac output | Restore circulating volume; control hemorrhage or fluid loss; vasopressor only if perfusion remains inadequate |
Cardiogenic | Pump failure → low cardiac output, often high filling pressures | Revascularize/treat cause; cautious volume; use vasopressor for hypotension and inotrope when low output persists |
Obstructive | Mechanical limitation to filling or outflow | Definitive relief of obstruction is central; vasoactive support is temporary |
Hypotension is common in shock, but the diagnosis also requires evidence of inadequate tissue perfusion. Mental status, skin temperature, urine output, lactate trend, acid-base status, ECG, and end-organ function help determine whether the resuscitation is working (Wood, 2026).
Fluids Are a Drug
Balanced crystalloids or saline may be appropriate for intravascular volume replacement depending on the clinical problem, while hemorrhagic shock often requires early blood products rather than repeated large crystalloid loads. Reassess after each intervention. A fluid bolus that increases filling pressure without improving stroke volume or perfusion can worsen pulmonary edema and tissue congestion. After shock resolves, fluid accumulation syndrome may require deresuscitation with fluid restriction, diuresis, or kidney replacement therapy (Wood, 2026).
For sepsis-induced hypoperfusion or septic shock, the 2026 Surviving Sepsis Campaign suggests at least 30 mL/kg IV crystalloid during the first 3 hours. Reassess frequently and individualize fluid administration when overload risk is high. Use dynamic measures of fluid responsiveness when available; norepinephrine is the preferred initial vasopressor for septic shock. This pathway should not be generalized to cardiogenic or hemorrhagic shock (Prescott et al., 2026). The initial MAP target is approximately 65 mm Hg for most adults. For adults aged 65 or older, the guideline conditionally suggests an initial target of 60–65 mm Hg, adjusted to perfusion (Prescott et al., 2026).
Crystalloids, Colloids, and Blood Products Are Not Interchangeable
Isotonic crystalloids remain first-line volume replacement for most hypovolemic shock. Albumin can expand intravascular volume in selected circumstances. Synthetic colloids such as starches and dextrans are not routine alternatives because of kidney injury, coagulopathy, and other harms. Hyperoncotic 25% albumin is not a substitute for volume resuscitation in hypovolemic shock. Hemorrhagic shock is different: blood components and rapid hemostasis should replace repeated large crystalloid loads when clinically significant blood loss is present. Massive-transfusion protocols increasingly use balanced component resuscitation and coagulation-guided therapy rather than red-cell-only replacement (Wood, 2026).
Vasopressors: Restore Vascular Tone
Agent | Typical IV dose | Best fit / limitation |
|---|---|---|
Norepinephrine | 0.01–0.4 mcg/kg/min (illustrative ICU weight-based protocol; label uses 8–12 mcg/min initially) (Hospira, Inc., 2025) | Common ICU weight-based titration differs from the FDA label’s non–weight-based starting rate (8–12 mcg/min) and typical maintenance (2–4 mcg/min). Titrate to perfusion and watch for ischemia. |
Epinephrine | 0.05–2 mcg/kg/min for septic-shock hypotension (FDA-labeled) (Baxter Healthcare Corporation, 2026) | Labeled septic-shock infusion range; lower doses sometimes used in other hemodynamic protocols. Watch for tachyarrhythmias, hyperglycemia, and lactate elevation. |
Phenylephrine | 0.5–6 mcg/kg/min for septic/other vasodilatory shock (FDA-labeled) (Eugia US LLC, 2026) | No IV bolus for septic or other vasodilatory shock; not routine first-line septic-shock vasopressor. Pure alpha agonism may reduce cardiac output; perioperative dosing is different. |
Vasopressin | 0.01–0.07 units/min in septic shock (FDA-labeled); commonly 0.03 units/min as ICU adjunct (American Regent, Inc., 2024) | Used as an adjunct to catecholamines for vasodilatory shock. The common fixed adjunct dose is not the full FDA-labeled septic-shock range. Monitor ischemia and cardiac output. |
Vasopressors are appropriate when profound hypotension or organ hypoperfusion persists despite correction of the primary problem and appropriate volume strategy. In cardiogenic shock, excessive vasoconstriction can raise afterload and further reduce cardiac output, so BP and perfusion must be interpreted together (Wood, 2026).
Inotropes: Increase Cardiac Output When Contractility Is the Limiting Problem
Agent | Typical IV dose | High-yield distinction |
|---|---|---|
Dobutamine | Usually 2.5–20 mcg/kg/min in clinical protocols; certain labels advise starting at 0.5–1 mcg/kg/min and titrating. Label-specific usual ranges differ (2.5–15 or 2–20 mcg/kg/min). | Beta1-predominant inotrope; titrate to cardiac output/perfusion, BP, heart rate, and ectopy. May increase tachyarrhythmias and occasionally decrease BP via vasodilation (DailyMed, n.d.-a, n.d.-b). Labeled-product reference: Hikma Pharmaceuticals USA Inc. (2024); dosing is formulation- and protocol-dependent. |
Milrinone | Labeled maintenance infusion: 0.375–0.75 mcg/kg/min. Lower starting rates (e.g., 0.125–0.25 mcg/kg/min) may be used in selected ICU protocols; reduce rate in renal impairment. | PDE3 inhibitor/inodilator; hypotension and tachyarrhythmia risk. The label provides creatinine-clearance-based infusion adjustments; monitor BP, rhythm, renal function, and electrolytes. |
Dopamine | Typically 5–20 mcg/kg/min in shock protocols; FDA labeling begins at 2–5 mcg/kg/min (Hikma Pharmaceuticals USA Inc., 2024) | Dose-dependent effects; more tachyarrhythmias than norepinephrine. Do not use “renal-dose dopamine” to prevent or treat AKI. |
In cardiogenic shock, a common pattern is norepinephrine to support perfusion pressure plus dobutamine when persistent low cardiac output remains. Milrinone may be useful in selected patients, including those chronically receiving beta blockers, but renal clearance and vasodilatory hypotension require particular caution (Ng & Yeung, 2026; Wood, 2026).
Agent Selection by Clinical Pattern
Cardiogenic Shock
Treat the underlying cause, often acute MI or advanced HF, while supporting perfusion. Revascularization, mechanical circulatory support, arrhythmia treatment, and decongestion may be as important as the vasoactive drug. Norepinephrine is often used when MAP is inadequate; add an inotrope if low cardiac output persists despite acceptable filling and pressure. Avoid reflex fluid loading in a congested patient with high filling pressures (Wood, 2026).
Hypovolemic or Hemorrhagic Shock
Restore circulating volume and stop the loss. Hemorrhagic shock increasingly emphasizes balanced blood-product resuscitation and hemostasis rather than large crystalloid volumes. Vasopressors can be used temporarily when hypotension threatens organ perfusion, but they do not replace volume restoration or bleeding control (Wood, 2026).
Traumatic Hemorrhage and Tranexamic Acid
Tranexamic acid (TXA) is an antifibrinolytic adjunct, not a substitute for bleeding control or balanced blood-product resuscitation. For trauma patients with active or anticipated significant hemorrhage, the 2023 European guideline recommends TXA as soon as possible and within 3 hours of injury: 1 g IV over 10 minutes, followed by 1 g IV over 8 hours. Treatment follows a trauma-hemorrhage protocol and is not routine for nonhemorrhagic hypovolemia (Rossaint et al., 2023; Wood, 2026).
Obstructive Shock
Vasopressors and fluids may support perfusion temporarily. Definitive treatment requires relieving the obstruction, whether by decompressing a tension pneumothorax, treating tamponade, or pursuing reperfusion or embolectomy for massive PE. Medication cannot compensate indefinitely for an unresolved mechanical obstruction (Wood, 2026).
Monitoring Is Part of the Prescription
- Continuous BP/ECG monitoring; arterial pressure monitoring when needed for titration.
- Mental status, capillary refill/skin perfusion, urine output, lactate trend, acid-base status, and kidney/liver function.
- Arrhythmias and myocardial ischemia with catecholamines and inotropes.
- Peripheral ischemia and excessive vasoconstriction with vasopressors.
- Fluid balance, pulmonary congestion, and cumulative positive balance after initial resuscitation.
- Central access is preferred for prolonged vasoactive therapy, but carefully monitored peripheral initiation can be appropriate while definitive access is obtained.
High-Yield Distinctions
- A higher MAP is not automatically better if cardiac output and tissue perfusion worsen.
- Norepinephrine is generally preferred over dopamine because it produces fewer arrhythmias.
- Dobutamine increases contractility; milrinone is an inodilator and requires renal dose adjustment.
- Vasopressin is generally an adjunct rather than the sole first-line vasoactive drug.
- Fluids can become harmful when they increase congestion without improving perfusion.
- Shock treatment is successful when end-organ perfusion improves – not when the monitor displays a single acceptable BP value.
Dosing note: The shock table includes both product-labeled dose ranges and examples from ICU protocols. Check the exact formulation, shock indication, clinical response, and institutional protocol; a dosing range used in one shock phenotype must not be applied indiscriminately to another (American Regent, Inc., 2024; Eugia US LLC, 2026; Hikma Pharmaceuticals USA Inc., 2024; Hospira, Inc., 2025; Wood, 2026).
Related YourDNP Resources
- Heart Failure Pharmacotherapy
- Acute Coronary Syndromes Pharmacotherapy
- Venous Thromboembolism Pharmacotherapy
- Acute Kidney Injury
Content last reviewed:
References
American Regent, Inc. (2024). Vasopressin injection [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ab267f4-9ec9-44fd-8521-f975074667d9
Baxter Healthcare Corporation. (2026). Epinephrine injection [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef556382-9d19-4f0e-9dbe-fcecc772a3e2
Eugia US LLC. (2026). Phenylephrine hydrochloride injection [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2ba1b3e-94bc-494d-b0fe-4ab9dd61dddc
Hikma Pharmaceuticals USA Inc. (2024). Dobutamine injection, USP [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74ba9408-17d3-48ac-be0b-a4fee9e7a1a5
Hikma Pharmaceuticals USA Inc. (2024). Dopamine hydrochloride injection [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e499952-46c7-4172-8c70-186312e240a3
Hospira, Inc. (2025). Levophed (norepinephrine bitartrate) injection [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4de72a8-2a75-4984-ce90-e4870226dc12
Ng, T. M. H., & Yeung, S. L. (2026). Heart failure. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 184-238). McGraw Hill.
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., Evans, L., Gershengorn, H. B., Hodgson, C. L., Honarmand, K., Kesecioglu, J., McIntyre, L., Mer, M., Nunnally, M. E., Oczkowski, S. J. W., . . . Coopersmith, C. M. (2026). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2026. Critical Care Medicine, 54(4), 725–812. https://doi.org/10.1097/CCM.0000000000007075
Rossaint, R., Afshari, A., Bouillon, B., Cerny, V., Cimpoesu, D., Curry, N., Duranteau, J., Filipescu, D., Grottke, O., Grønlykke, L., Harrois, A., Hunt, B. J., Kaserer, A., Komadina, R., Madsen, M. H., Maegele, M., Mora, L., Riddez, L., Romero, C. S., . . . Spahn, D. R. (2023). The European guideline on management of major bleeding and coagulopathy following trauma: Sixth edition. Critical Care, 27, Article 80. https://doi.org/10.1186/s13054-023-04327-7
Wood, G. C. (2026). Circulatory shock syndromes. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 525-547). McGraw Hill.